Final Oncology Asset (Lisavanbulin) Divested
Basilea Pharmaceutica has announced an asset purchase agreement with the Glioblastoma Foundation for lisavanbulin (BAL101553), the...
top of page
Adam Strydom
- May 31
- 1 min
Can We Make NHI More Affordable?
ALG Newsletter - Can we make NHI more affordable? We look at the signing of the NHI Bill from a slightly different perspective. Can...
00
Adam Strydom
- May 21
- 1 min
Cresemba Milestone Payments Continue to Roll in
Basilea Pharmaceutica has announced the triggering of a US$1.25m milestone payment from Pfizer, triggered by sustained strong sales of...
00
Adam Strydom
- Apr 18
- 1 min
CARB-X Grant for Preclinical Programs
In the lead up to its capital markets day, Basilea Pharmaceutica announced it has received initial funding of up to US$0.9m through a...
10
Adam Strydom
- Apr 18
- 1 min
Positive Signals Abound
SIGA Technologies announced a strategic step in fortifying its distribution partner, Meridian, allowing greater control over planning and...
00
Adam Strydom
- Apr 18
- 1 min
Zevtera Crosses Key US Regulatory Hurdle
Basilea Pharmaceutica has announced the FDA approval of its second lead asset, Zevtera (ceftobiprole), for the treatment of severe...
00
Adam Strydom
- Mar 19
- 1 min
Onwards and Upwards with Strong FY23
SIGA Technologies has delivered its best top-line performance in the last five years, supported by a late surge in TPOXX deliveries...
50
Adam Strydom
- Feb 27
- 1 min
From Strength to Strength
FY23 was another strong year for Basilea Pharmaceutica, marked by successive guidance beats and meaningful progress in fortifying its...
30
Adam Strydom
- Feb 13
- 1 min
Antibiotic addition to further replenish pipeline
Basilea Pharmaceutica has announced a preclinical antibiotic programme asset purchase agreement, aligning with management’s pre-emptive...
10
Adam Strydom
- Jan 24
- 1 min
Growth Pivot with Potential Antibacterial Addition
Basilea Pharmaceutica has announced an exclusive evaluation licence and option agreement with South Korea-based iNtRON Biotechnology...
10
Adam Strydom
- Jan 22
- 1 min
FDA Accepts New Drug Application for Ceftobiprole
Basilea Pharmaceutica has announced that the US FDA has accepted its New Drug Application (NDA) for ceftobiprole. The FDA has set a...
20
Adam Strydom
- Jan 19
- 1 min
Differentiating Immunotherapy Truths vs Opinion
Personalised treatment continues to be a major theme observed at the annual American Society of Clinical Oncology (ASCO) meeting, much...
10
All
bottom of page